Phase 1 of the DMT stroke study has just begun, with the first patient being dosed yesterday. The first part of the study will use a single-escalating dose design aimed at identifying a safe and tolerable dose that will not produce psychedelic effects, in which they will then focus on seeing the effects of DMT to support the recovery of stroke victims. With the stroke management market worth above $30B, why DMT?
- DMT is an agonist of multiple receptors, including sigma-1 receptor. It is a multi-faceted stress-responsive receptor which promotes cell survival, neuroprotection, neuroplasticity, and neuroimmunomodulation (basically promotes brain health and recovery).
- DMT also aids in releasing Brain-Derived Neurotrophic Factor, a protein that helps in stroke recovery.
- DMT is an already established and safe drug, so I’m sure that there will be no problems with the safety side of things as they continue to look into the effects on stroke patients.
https://youtu.be/BfjAjt1jxuU
With $AGN.C continuing to explore the uses of drug repurposing, there’s a ton of potential considering some of their other research on IPF and chronic cough, of which they have already received an FDA orphan designation. Overall, considering the current $5M valuation, this could become extremely interesting as with pharmaceutical companies, once approval is given, there’s so much upside potential.